Skip to main content
. Author manuscript; available in PMC: 2021 Aug 18.
Published in final edited form as: Nat Med. 2015 Jul 20;21(8):922–926. doi: 10.1038/nm.3884

Figure 1.

Figure 1

Tumor response to ibrutinib therapy. (a) Waterfall plot of maximum change from baseline of SPD of lymph nodes for subjects with evaluable tumors (n = 43). (b) Overall response rate by DLBCL subtype. Fisher’s exact test of the overall response rate between the ABC and GCB groups (*P = 0.0106). Fractions above the bars represent the number of subjects showing a complete or partial response (numerator) over the total number of subjects in the group (denominator). (c) Kaplan–Meier analysis of progression-free survival. Log-rank test for analysis between groups (**P = 0.0038). (d) Kaplan–Meier analysis of overall survival. Log-rank test for analysis between groups (***P = 0.056). ABC, activated B cell–like; GCB, germinal center B cell–like; DLBCL, diffuse large B cell lymphoma; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response; SPD, sum of the product of the diameters.

HHS Vulnerability Disclosure